DiagnaMed Expands Clean Hydrogen Energy Extraction Capabilities to Demonstrate Proof of Concept of Proprietary Technology

Rhea-AI Summary

DiagnaMed Holdings Corp. (DGNMF) has announced a strategic acquisition in Ontario to demonstrate its proprietary hydrogen extraction technology. The acquisition serves as a proof of concept for the company's clean hydrogen energy solutions and aligns with the Ontario Hydrogen Innovation Fund's recent $30 million investment initiative. The fund supports projects integrating low-carbon hydrogen across various sectors. CEO Fabio Chianelli emphasized that this acquisition is crucial for validating their technology while positioning DiagnaMed to advance sustainable hydrogen development within Ontario's innovation ecosystem.

Positive

• Strategic acquisition provides real-world validation opportunity for proprietary hydrogen extraction technology
• Alignment with Ontario Hydrogen Innovation Fund's $30 million investment initiative enhances market positioning
• Expansion into clean hydrogen technology demonstrates commitment to growing cleantech sector

Negative

• Financial terms and specific details of the acquisition not disclosed
• No immediate revenue impact mentioned
• Proof of concept stage indicates early phase development with uncertain commercial viability

TORONTO, June 05, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, is pleased to announce its recent strategic acquisition in Ontario, serving as a critical proof of concept for the Company's proprietary hydrogen extraction technology, directly aligning with its commitment to clean hydrogen energy solutions.

This acquisition strategically positions DiagnaMed to validate and demonstrate its hydrogen extraction technology in practical, real-world applications. Additionally, this initiative complements the goals of the Ontario Hydrogen Innovation Fund, which recently announced a $30 million investment to support projects that integrate low-carbon hydrogen across various sectors, further reinforcing DiagnaMed's position as a leader in sustainable hydrogen development.

"This strategic acquisition represents a pivotal step in validating and showcasing our proprietary hydrogen extraction technology," stated Fabio Chianelli, President and CEO of DiagnaMed. "Leveraging Ontario’s supportive innovation ecosystem and aligning with initiatives such as the Ontario Hydrogen Innovation Fund, DiagnaMed is positioned to significantly advance sustainable hydrogen development and contribute meaningfully to the cleantech life sciences sector."

About DiagnaMed

DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a Canadian technology innovator specializing in advanced hydrogen extraction technologies designed to support the rapidly growing natural hydrogen industry. Focused on commercial scalability, DiagnaMed aims to deliver cost-effective, sustainable, and efficient hydrogen solutions critical for global energy security and decarbonization. Visit DiagnaMed.com.

For more information, please contact:

Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

Certain statements in this news release are forward-looking statements, including with respect to future plans, and other matters. Forward-looking statements consist of statements that are not purely historical, including any statements regarding beliefs, plans, expectations or intentions regarding the future. Such information can generally be identified by the use of forwarding-looking wording such as “will”, “may”, “expect”, “could”, “can”, “estimate”, “anticipate”, “intend”, “believe”, “projected”, “aims”, and “continue” or the negative thereof or similar variations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, including but not limited to, business, economic and capital market conditions, the ability to manage operating expenses, and dependence on key personnel. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs, and the ability to achieve goals. Factors that could cause the actual results to differ materially from those in forward-looking statements include, the continued availability of capital and financing, litigation, failure of counterparties to perform their contractual obligations, loss of key employees and consultants, and general economic, market or business conditions. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the Three and Six Months Ended March 31, 2025 (“MD&A”), dated May 28, 2025, which is available on the Company's profile at www.sedarplus.ca. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The reader is cautioned not to place undue reliance on any forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release. Except as required by law, the Company disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “1933 Act”) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. Persons (as defined in Regulation S under the 1933 Act) unless registered under the 1933 Act and applicable state securities laws, or an exemption from such registration requirements is available.

FAQ

What is the purpose of DiagnaMed's (DGNMF) recent acquisition in Ontario?

The acquisition serves as a proof of concept for DiagnaMed's proprietary hydrogen extraction technology and aims to demonstrate its capabilities in real-world applications.

How does DiagnaMed's acquisition align with the Ontario Hydrogen Innovation Fund?

The acquisition aligns with the Fund's $30 million investment initiative to support projects integrating low-carbon hydrogen across various sectors.

Who is the CEO of DiagnaMed Holdings Corp (DGNMF)?

Fabio Chianelli is the President and CEO of DiagnaMed Holdings Corp.

What is DiagnaMed's (DGNMF) primary technology focus?

DiagnaMed specializes in advanced hydrogen extraction technologies and clean hydrogen energy solutions.

What stock exchanges is DiagnaMed listed on?

DiagnaMed is listed on the Canadian Securities Exchange (CSE: DMED) and the OTCQB market (OTCQB: DGNMF).